Omeros Corporation (FRA:3O8)
Germany · Delayed Price · Currency is EUR | Market Cap | 724.57M +41.7% |
| Revenue (ttm) | n/a |
| Net Income | -103.26M |
| EPS | -1.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 9.98 |
| Previous Close | 10.11 |
| Day's Range | 9.98 - 10.25 |
| 52-Week Range | 2.49 - 15.46 |
| Beta | n/a |
| RSI | 54.50 |
| Earnings Date | Mar 12, 2026 |
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind... [Read more]
News
Omeros (OMER) Shows Promising Results in Early Cancer Treatment Study
Omeros (OMER) Shows Promising Results in Early Cancer Treatment Study
Omeros Announces Successful Primate Study in OncotoX-AML Drug Program
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform....
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ca...
Omeros (OMER) Rises on First Shipments of Yartemlea
Omeros (OMER) Rises on First Shipments of Yartemlea
Omeros higher after first commercial sales of transplant therapy
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA
Omeros Announces First Commercial Sales of YARTEMLEA®
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orde...
Omeros Corp To Discuss FDA approval of YARTEMLEA Transcript
Omeros Corp To Discuss FDA approval of YARTEMLEA Transcript
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment January 7, 2026 4:30 PM ESTCompany...
Omeros prices transplant complication drug at $36,000 per dose
Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a c...
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options
Investors eyeing a purchase of Omeros Corp (Symbol: OMER) stock, but cautious about paying the going market price of $15.34/share, might benefit from considering selling puts among the alternative str...
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)
Omeros Announces New Date for YARTEMLEA Approval Conference Call
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA (narsoplimab-wuug), the first and only therapy indicated for he...
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and on...
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday. Shares of Biohaven Ltd (NYSE: BHVN) fell sharply in pre-market trading after the company reported that ...
Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today
Wall Street experienced a modest rally as the S&P 500 reached new heights, closing up 0.2% in a shortened session before the Christmas break. The index’s year-to-date gains now stand at 17%. The Dow J...
Why Omeros Stock Skyrocketed Today
The company is on the brink of commercializing a unique medication.
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely
Gold Edges Lower; Omeros Shares Jump
U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday. the Dow traded up 0.48% to 48,673.55 while the NASDAQ rose 0.09% to 23,582.81. The...
Gold Edges Lower; Omeros Shares Jump
U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday.
Wednesday Sector Leaders: Drugs, Biotechnology Stocks
In trading on Wednesday, drugs shares were relative leaders, up on the day by about 1.6%. Leading the group were shares of Omeros, up about 84.5% and shares of Dynavax Technologies up about 38.6% on t...
OMER Surges 81% On FDA Approval Of Yartemlea For Transplant-Related TA-TMA
(RTTNews) - Omeros Corporation (OMER) jumped 81.14%, closing at $15.85, up $7.10, after the U.S. FDA approved Yartemlea (narsoplimab-wuug) for the treatment of transplant-associated thrombotic microan...
Omeros (OMER) Secures FDA Approval for Breakthrough Treatment
Omeros (OMER) Secures FDA Approval for Breakthrough Treatment
FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication
The FDA has approved Omeros Corporation's ... Full story available on Benzinga.com